<DOC>
	<DOCNO>NCT00740116</DOCNO>
	<brief_summary>The purpose study determine standardize single dose tranexamic acid give intravenously immediately preoperatively reduces perioperative bleeding volume reduces need blood transfusion woman undergo surgery advance ovarian cancer .</brief_summary>
	<brief_title>Tranexamic Acid Surgery Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Females age 18 old pelvic abdominal tumor suspect histopathologically proven ovarian cancer FIGO stage IIIV undergoing primary surgery intention perform optimal cytoreductive radical surgery . Understand speak Swedish Accept participation study write verbal information sign inform consent . Allergy tranexamic acid Having tranexamic acid within recent 30 day Previous present episode thromboembolic event . Previous present treatment within recent 3 month anticoagulant . Previous present know coagulopathy Myocardial infarction within previous 12 month instable angina pectoris , accord investigator , may increase risk complication significantly case lower hemoglobin . Significant renal failure serumcreatinine &gt; 250 Âµmol/l . Severe psychiatric dysfunction mentally substantially disable .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Tumor ovary</keyword>
	<keyword>Surgical blood loss</keyword>
	<keyword>Postoperative blood loss</keyword>
	<keyword>Preventive therapy</keyword>
	<keyword>Thromboembolism</keyword>
</DOC>